No products in the cart.
Pre-made Azintuxizumab benchmark antibody ( Whole mAb ADC, anti-SLAMF7/CS1 therapeutic antibody, Anti-19A/CD319/CRACC Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-043
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Azintuxizumab biosimilar, Whole mAb ADC, Anti-SLAMF7/CS1 Antibody: Anti-19A/CD319/CRACC therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
| Products Name (INN Index) | Pre-Made Azintuxizumab biosimilar, Whole mAb ADC, Anti-SLAMF7/CS1 Antibody: Anti-19A/CD319/CRACC therapeutic antibody |
|---|---|
| INN Name | Azintuxizumab |
| Target | SLAMF7 |
| Format | Whole mAb ADC |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2016 |
| Year Recommended | 2017 |
| Companies | AbbVie |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Multiple myeloma |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | SLAMF7/CS1 |
| Package |
Previous slide
Next slide
